

## Special Issue

# Optimized Antibody Therapy for Acute Blood Diseases

### Message from the Guest Editors

The diseases and indications for antibody therapy are growing rapidly, and have extended from leukemias and lymphomas to antibody-mediated autoimmune diseases, non-malignant hematology and hemostaseology. Indispensable for the effect of a therapeutic antibody is not only a wise choice of antigen or target, but also the nature of the Fc fragment—whether it is humanized and which IgG subclass it consists of. The antibodies display their activity by antibody-dependent cytotoxicity or complement activation. Some antibodies have been coupled to a drugs to induce direct cytotoxicity. Bi- or trispecific antibodies have been introduced, simultaneously engaging tumor cells and autologous immune cells or binding more than one antigen on a target cell. Recently, checkpoint inhibitors have been used against a variety of tumors, inducing a non-specific immune stimulation. Current clinical trials are investigating the combination of such checkpoint inhibitors with tumor-specific monoclonal antibodies. Many questions remain unanswered, such as the optimal time point to introduce antibody therapy or mechanisms to enhance their activity or obtain synergistic effects.

### Guest Editors

Prof. Dr. Rupert Handgretinger

1. Senior Professor, Department of Hematology/Oncology, Children's Hospital, University Hospital Tübingen, 72076 Tübingen, Germany
2. George and Jennifer Yeo Endowed Chair in Pediatric Oncology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Dr. Manon Queudeville

Department I—General Pediatrics, Hematology/Oncology, Children's Hospital, University Hospital Tübingen, 72076 Tübingen, Germany

### Deadline for manuscript submissions

closed (20 October 2022)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/116971](https://mdpi.com/si/116971)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).